Key result
Human pluripotent stem cell-derived cardiomyocytes effectively recapitulate many molecular, cellular, and functional aspects of human heart pathophysiology, serving as valuable in vitro models for disease modeling and drug screening.
Answers are grounded in this paper and cite their sources.
Human pluripotent stem cell-derived cardiomyocytes provide a valuable in vitro platform for modeling cardiovascular diseases and drug screening, despite ongoing challenges with cell maturity and reproducibility.
Technical advances in generating and phenotyping cardiomyocytes from human pluripotent stem cells (hPSC-CMs) are now driving their wider acceptance as in vitro models to understand human heart disease and discover therapeutic targets that may lead to new compounds for clinical use. Current literature clearly shows that hPSC-CMs recapitulate many molecular, cellular, and functional aspects of human heart pathophysiology and their responses to cardioactive drugs. Here, we provide a comprehensive overview of hPSC-CMs models that have been described to date and highlight their most recent and remarkable contributions to research on cardiovascular diseases and disorders with cardiac traits. We conclude discussing immediate challenges, limitations, and emerging solutions.
No takes yet. Share an insight, caveat, or question.
Giacomelli et al. (2017) conducted a review in Cardiovascular diseases and disorders with cardiac traits. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) was evaluated. Human pluripotent stem cell-derived cardiomyocytes effectively recapitulate many molecular, cellular, and functional aspects of human heart pathophysiology, serving as valuable in vitro models for disease modeling and drug screening.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: